{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-fda-clinical-hold-partial-hold-communications-and-remediation”
},
“headline”: “SOP for FDA Clinical Hold/Partial Hold Communications and Remediation”,
“description”: “This SOP defines procedures for managing FDA-imposed clinical hold or partial hold under 21 CFR 312.42. It covers sponsor and investigator responsibilities, communication with FDA and IRB, remediation actions, timelines, and resumption of trial activities.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for FDA Clinical Hold/Partial Hold Communications and Remediation

Purpose

The purpose of this SOP is to outline procedures for managing communications and remediation when the U.S. Food and Drug Administration (FDA) imposes a clinical hold or partial hold on an IND-regulated study under 21 CFR 312.42. It ensures timely resolution, protection of subject safety, and compliance with regulatory requirements.

Scope

This SOP applies to sponsors, investigators, CROs, regulatory affairs, and QA teams involved in clinical trials under IND oversight. It covers receipt of FDA hold notifications, communication with sites, subject safety measures, remediation planning, submissions to FDA, and trial resumption.

Responsibilities

• Sponsor: Coordinates responses to FDA, prepares remediation plans, and oversees CAPA implementation.
• Investigator: Ensures trial suspension at site level, safeguards subjects, and communicates with IRB.
• CRO: Assists in tracking corrective actions and monitors site compliance during hold.
• Regulatory Affairs: Manages FDA communications and formal submissions.
• QA: Audits remediation and ensures inspection readiness.
• IRB/EC: Reviews site-level implications and safety measures.

Accountability

The Sponsor’s Regulatory Head is accountable for ensuring compliance with FDA hold requirements. Investigators are accountable for site-level trial suspension and subject safety.

Procedure

1. Receipt of FDA Hold Notification
1.1 Document FDA hold letter upon receipt.
1.2 Record in Clinical Hold Log (Annexure-1).

2. Immediate Actions
2.1 Suspend subject enrollment immediately.
2.2 Notify investigators, CRO, and IRB.
2.3 Ensure subject safety monitoring continues.
2.4 Record in Site Notification Log (Annexure-2).

3. Root Cause Analysis and Remediation
3.1 Conduct investigation into issues cited by FDA.
3.2 Develop corrective and preventive action (CAPA) plan.
3.3 Document in Remediation Log (Annexure-3).

4. FDA Communication
4.1 Submit remediation plan to FDA within required timelines.
4.2 Maintain FDA Communication Log (Annexure-4).

5. Site and Subject Management
5.1 Inform subjects if their participation is affected.
5.2 Provide alternative medical care where needed.
5.3 Document in Subject Communication Log (Annexure-5).

6. Trial Resumption
6.1 Resume study activities only after FDA issues “Hold Lifted” notification.
6.2 Record in Trial Resumption Log (Annexure-6).

7. Archiving
7.1 Archive hold-related correspondence, CAPA documentation, and FDA responses in TMF and ISF.
7.2 Retain per regulatory timelines.

Abbreviations

• SOP: Standard Operating Procedure
• CAPA: Corrective and Preventive Action
• FDA: Food and Drug Administration
• IND: Investigational New Drug
• IRB/EC: Institutional Review Board/Ethics Committee
• CRO: Contract Research Organization
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. Clinical Hold Log (Annexure-1)
2. Site Notification Log (Annexure-2)
3. Remediation Log (Annexure-3)
4. FDA Communication Log (Annexure-4)
5. Subject Communication Log (Annexure-5)
6. Trial Resumption Log (Annexure-6)

References

• 21 CFR 312.42 – Clinical Hold and Termination
• FDA – Guidance on Clinical Holds
• ICH GCP E6(R2)

Version: 1.0

Approval Section

Annexures

Annexure-1: Clinical Hold Log

Annexure-2: Site Notification Log

Annexure-3: Remediation Log

Annexure-4: FDA Communication Log

Annexure-5: Subject Communication Log

Annexure-6: Trial Resumption Log

Revision History

For more SOPs visit: Pharma SOP